

## Statin Therapy for the Prevention and Treatment of Cardiovascular Disease Measure Narrative

<b>Description</b>	Percentage of high-risk adult patients aged $\geq 21$ years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR adult patients aged $\geq 21$ years with a fasting or direct Low-Density Lipoprotein Cholesterol (LDL-C) level $\geq 190$ mg/dL; OR patients aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL; who were prescribed or are already on statin medication therapy during the measurement year.	
<b>Methodology</b>	Population identification is accomplished via a query of a practice management system or Electronic Medical Record (EMR) to identify the population of eligible patients (denominator). Data elements are either extracted from an EMR system or abstracted through medical record review.	
<b>Measurement Period</b>	January 1 through December 31, 20xx	
<b>Eligible Population</b>	<b>Eligible Specialties</b>	Family Medicine, Internal Medicine, Geriatric Medicine, Endocrinology, Cardiology
	<b>Eligible Providers</b>	Medical Doctor (MD), Doctor of Osteopathy (DO), Physician Assistant (PA), Advanced Practice Registered Nurses (APRN)
	<b>Ages</b>	21 years and older as of January 1 of the measurement period
	<b>Event</b>	At least one face to face visit (Value Sets: <i>Annual Wellness Visit; Face-to-Face Interaction; Office Visit; Preventive Care Services – Established Office Visit, 18 and Up; Preventive Care Services – Initial Office Visit, 18 and Up</i> ) with an eligible provider in an eligible specialty for any reason during the measurement period.
<b>Exclusions</b>	None	
<b>Denominator</b>	<p>Patients who met any of the following criteria are identified as at high risk of a cardiovascular event and included in the denominator:</p> <ul style="list-style-type: none"> <li>• active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) during the current measurement period or any time prior (Value Sets: <i>PCI, Acute Myocardial Infarction, Ischemic Vascular Disease, Hemorrhagic Stroke, Ischemic Stroke, CABG Surgeries, Carotid Intervention</i>);</li> <li>• LDL-C result <math>\geq 190</math> mg/dL at any time during or prior to the measurement period;</li> <li>• aged 40 – 75 years at the beginning of the measurement period with an active diagnosis of diabetes (<i>Diabetes</i> Value Set) with the highest LDL-C result of 70 – 189 mg/dL during the current measurement period or two years prior to the beginning of the measurement period.</li> </ul>	
<b>Numerator</b>	The number of patients with a statin medication ( <i>Statin RXNORM</i> Value Set) current on the medication list or prescribed a statin medication during the measurement period.	

## Statin Therapy for the Prevention and Treatment of Cardiovascular Disease Measure Narrative

<b>Denominator Exceptions</b>	<ul style="list-style-type: none"> <li>• Patients with adverse effect, allergy or intolerance to statin medication therapy (<i>Medical Reason SNOMED Value Set</i>)</li> <li>• Patients who have an active diagnosis of pregnancy or breastfeeding (<i>Breastfeeding Value Set</i>) (<i>Pregnancy Dx Value Set</i>)</li> <li>• Patients who are receiving palliative care (<i>Palliative Care Value Set</i>)</li> <li>• Patients with active liver disease or hepatic disease or insufficiency (<i>Liver Disease Value Set</i>)</li> <li>• Patients with end stage renal disease (<i>End Stage Renal Disease Care Value Set</i>)</li> <li>• Most recent LDL-C result &lt; 70 mg/dL for patients with a diabetes diagnosis who are not currently receiving statin medication therapy</li> </ul>
<b>Measure Scoring</b>	Rate/Proportion
<b>Interpretation of Score</b>	Higher score indicates better quality
<b>Measure Type</b>	Process